ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis expands gene-editing program

by Ryan Cross
November 20, 2017 | APPEARED IN VOLUME 95, ISSUE 46

A collaboration with Bedford, Mass.-based Homology Medicines will expand gene-editing research at Novartis. Homology’s gene-editing technique relies on recently discovered variants of adeno-associated viruses rather than on CRISPR. AAVs induce homologous recombination in a cell’s genome to swap out an old piece of DNA for a new one. The goal is to treat genetic blood and eye diseases. The financial terms are not disclosed, but Novartis previously invested in Homology as part of the firm’s $83.5 million series B funding.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment